Académique Documents
Professionnel Documents
Culture Documents
HBV HCV Hiv
HBV HCV Hiv
DNA
polymerase
Envelope
RNA primer
Small surface
antigen
Phaân phoái caùc loaïi genotypes
HBV (A to H) treân toøan caàu
A, D
G B, C
A, C, B, D, G
F, H A,D B, C
E
F A
CDC Fact Sheet. 2004; Lee. N Engl J Med. 1997; Lavanchy. J Viral Hepat. 2004.
Dieãn tieán töï nhieân
cuûa nhieãm HBV
5%-10% laø
ngöôøi
nhieãm HBV HCC
maïn tính
>30% laø
Nhieãm HBV Nhieãm ngöôøi VGSV
HBV B maïn tính Xô gan Gheùp gan Cheát
caáp
maïn tính
75
5-year
mortality
50
rates (%)
25
Meï – con + ++
Söû duïng kim tieâm oáng tieâm laø nguyeân nhaân laây
nhieãm
quan troïng HIV–HCV.
Tæ leä nhieãm HCV treân
ngöôøi nhieãm HIV
• Asia 26%
• Europe 33%
– Spain 50%
• USA 30%
– NY and Buffalo 40%
– Boston 56%
– Baltimore 97%*
• Australia 13.1%
* methadone clinic
Qu¸ tr×nh nhiÔm HCV
Makris Eyster
Soto Telfer
Pol Makris
Benhamou Lesens
Combined Combined
0.76 1.0 2.07 10.83 0.61 1.0 6.14 10 175.32
2000 HAART-treated
1800 people with HIV
1600 infection are living
1400 longer
1200
1000
800
600
400
200
0
1994
1988
1989
1990
1991
1992
1993
1995
1996
1997
1998
1999
2000
2001
2002
AIDS diagnoses Deaths
AIDS/HIV Quarterly Surveillance Tables 59:03/2, June 2003
Beänh gan hieän nay laø nguyeân
nhaân töû vong quan troïng khi söû
duïng HAART
Mortality from end-stage liver disease as a
percentage of all deaths among HIV patients
60
Pre-therapy era 50%
50 45%
Therapy era
Mortality (%)
40 35%
30
20
13% 12%
10 5%
0
Italy (Brescia) Spain (Madrid) USA (Boston)
Bica et al. Clin Infect Dis 2001;32:492–497
Puoti et al. JAIDS 2000;24:211–217
Soriano et al. Eur J Epidemiol 1999;15:1–4
Soriano et al. PRN Notebook 2002;7:10–15
Martin-Carbonero et al. AIDS Res Human Retrovirus 2001;17:1467–1471
Ñieàu trò VGSV C
Gaàn ñaây, ñieàu trò döïa vaøo coâng
thöùc:
Interferon alfa 3 MIU, 3 laàn/tuaàn, TDD
+
Ribavirin: uoáng 800–1200 mg/ngaøy.
Trong 24–48
tuaàn
Ñieàu trò VGSV C ít hieäu quaû
treân BN nhieãm HIV
SVR trong caùc nghieân cöùu vôùi interferon alfa + ribavirin trong 48 w
Hepatitis C only
60
50 43%
38%
SVR (%)
40
30
20
10
0
Poynard et al. McHutchison et
1998 al. 1998
n = 277 n = 228
Poynard et al. Lancet 1998;352:1426-1432
McHutchison et al. N Engl J Med 1998;339:1485-1492
Ñieàu trò VGSV C ít hieäu quaû
treân BN nhieãm HIV
SVR trong caùc nghieân cöùu vôùi interferon alfa + ribavirin trong 48 w
50 43%
38%
SVR (%)
40
30
20
8.4%
10
0
Poynard et al. McHutchison et Sulkowski et al.
1998 al. 1998 2004
n = 277 n = 228 n = 83
Poynard et al. Lancet 1998;352:1426-1432
McHutchison et al. N Engl J Med 1998;339:1485-1492; Sulkowski et al. JAIDS 2004;35:464-472
NÕu BN cã thÓ ®iÒu trÞ,
nªn ®iÒu trÞ?
0 24 48 72
Tuaàn
*860 patients received at least one dose of study medication Torriani et al. 11th CROI, 2004; abstract
39112
Ñaùp öùng sieâu vi – luùc ngöng trò
vaø theo doõi (genotype 1)
End of treatment End of follow-up
60
50
Response (%)
40 38%
29%
30
21%
20
14%
10 8% 7%
0
Roferon®-A PEGASYS® PEGASYS®
+ Ribavirin + placebo + Ribavirin
Virological response defined as < 50 IU/ml HCV RNA Torriani et al. 11th CROI, 2004; abstract 112
APRICOT: SVR
60 P 0.0001
P 0.0001
50
40%
Response (%)
40
P = 0.0084
30
20%
20
12%
10
n = 285 n = 286 n = 289
0
Roferon®-A PEGASYS® PEGASYS®
+ Ribavirin + placebo + Ribavirin
SVR defined as < 50 IU/ml HCV RNA at week 72; ITT Torriani et al. 11th CROI, 2004; abstract 112
Ñaùp öùng sieâu vi – luùc ngöng
trò vaø theo doõi (genotypes 2, 3)
Luùc ngöng ñieàu trò Luùc ngöng theo doõi
70 64% 62%
57%
60
50
Response (%)
36%
40
27%
30
20%
20
10
0
Roferon®-A PEGASYS® PEGASYS®
+ Ribavirin + placebo + Ribavirin
Virological response defined as < 50 IU/ml HCV RNA Torriani et al. 11th CROI, 2004; abstract 112
Dù phßng HCV